@dansfera: Is the reigning champion about to be dethroned? 🤯 This side-by-side comparison of a promising new therapy versus Gilead's cutting-edge (and costly!) Yescarta is *major*. If these comparable results continue to hold in larger trials, the implications for patient access are significant! Observing that the initial safety profile seems to be clearing hurdles where CRISPR has faced scrutiny—all while the current administration navigates its own evolving stance on gene therapy advancements. Big Pharma better be watching this shift! #GeneTherapy #MedTech #Biotech #FutureOfMedicine #HealthcareDisruption